Matthew O'Brien
Stock Analyst at Piper Sandler
(2.69)
# 2,014
Out of 4,735 analysts
29
Total ratings
75%
Success rate
9.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $140 → $115 | $110.52 | +4.05% | 12 | Jul 1, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $17 | $11.61 | +46.43% | 3 | May 8, 2024 | |
| PODD Insulet | Maintains: Neutral | $295 → $230 | $276.08 | -16.69% | 1 | Feb 24, 2022 | |
| KRMD KORU Medical Systems | Downgrades: Neutral | $9 → $4.5 | $4.14 | +8.70% | 1 | Jan 26, 2021 | |
| IART Integra LifeSciences Holdings | Maintains: Neutral | $53 → $47 | $25.12 | +87.10% | 8 | Oct 29, 2020 | |
| BAX Baxter International | Maintains: Overweight | $77 → $83 | $31.48 | +163.66% | 1 | Jul 27, 2018 | |
| ALGN Align Technology | Maintains: Overweight | $300 → $325 | $228.00 | +42.54% | 1 | May 24, 2018 | |
| DXCM DexCom | Reinstates: Overweight | $20 | $86.32 | -77.41% | 1 | May 22, 2017 | |
| MDXG MiMedx Group | Initiates: Overweight | $10 | $9.14 | +9.41% | 1 | Mar 3, 2017 |
Zimmer Biomet Holdings
Jul 1, 2024
Downgrades: Neutral
Price Target: $140 → $115
Current: $110.52
Upside: +4.05%
Alphatec Holdings
May 8, 2024
Maintains: Overweight
Price Target: $19 → $17
Current: $11.61
Upside: +46.43%
Insulet
Feb 24, 2022
Maintains: Neutral
Price Target: $295 → $230
Current: $276.08
Upside: -16.69%
KORU Medical Systems
Jan 26, 2021
Downgrades: Neutral
Price Target: $9 → $4.5
Current: $4.14
Upside: +8.70%
Integra LifeSciences Holdings
Oct 29, 2020
Maintains: Neutral
Price Target: $53 → $47
Current: $25.12
Upside: +87.10%
Baxter International
Jul 27, 2018
Maintains: Overweight
Price Target: $77 → $83
Current: $31.48
Upside: +163.66%
Align Technology
May 24, 2018
Maintains: Overweight
Price Target: $300 → $325
Current: $228.00
Upside: +42.54%
DexCom
May 22, 2017
Reinstates: Overweight
Price Target: $20
Current: $86.32
Upside: -77.41%
MiMedx Group
Mar 3, 2017
Initiates: Overweight
Price Target: $10
Current: $9.14
Upside: +9.41%